Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for improving survival of lymphoma study

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages 6027-6032

  Kim, Seok Jin ^a   Kim, Kihyun ^a   Kim, Byung Soo ^a   Kim, Chul Yong ^a   Suh, Cheolwon ^a   Huh, Jooryung ^a   Lee, Sang Wook ^a   Kim, Jin Seok ^a   Cho, Jaeho ^a   Lee, Gyeong Won ^a   Kang, Ki Mun ^a   Eom, Hyeon Seok ^a   Pyo, Hong Ryull ^a   Ahn, Yong Chan ^a   Ko, Young Hyeh ^a   Kim, Won Seog ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD20 ANTIBODY; CD56 ANTIGEN; CISPLATIN; CREATININE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BLOOD SAMPLING; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOTOXICITY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; ENDOSCOPY; EPSTEIN BARR VIRUS; EXTRANODAL NATURAL KILLER T CELL LYMPHOMA; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRITIS; HUMAN; IMMUNOPHENOTYPING; LEUKOPENIA; LYMPHOMA; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SIMULATION; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UREMIA; VIRUS LOAD; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NK T CELL LYMPHOMA; NOSE TUMOR; PATHOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT; SOUTH KOREA; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOSE NEOPLASMS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; REPUBLIC OF KOREA; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73349087528     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.8592     Document Type: Article

References (25)

1. Kim WS, Song SY, Ahn YC, et al: CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 12:349-352, 2001
2. Kim BS, Kim TY, Kim CW, et al: Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy: Result of chemotherapy in NK/T-cell lymphoma. Acta Oncol 42:779-783, 2003
3. Kim SJ, Kim BS, Choi CW, et al: Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leuk Lymphoma 47:1265-1273, 2006
4. Yamaguchi M, Kita K, Miwa H, et al: Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76:2351-2356, 1995
5. Drenou B, Lamy T, Amiot L, et al: CD3-CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 89:2966-2974, 1997
6. Cheung MM, Chan JK, Lau WH, et al: Early stage nasal NK/T-cell lymphoma: Clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54:182-190, 2002
7. Chim CS, Ma SY, Au WY, et al: Primary nasal natural killer cell lymphoma: Long-term treatment outcome and relationship with the International Prognostic Index. Blood 103:216-221, 2004
8. Li YX, Yao B, Jin J, et al: Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 24:181-189, 2006
9. Chen HH, Fong L, Su IJ, et al: Experience of radiotherapy in lethal midline granuloma with special emphasis on centrofacial T-cell lymphoma: A retrospective analysis covering a 34-year period. Radiother Oncol 38:1-6, 1996
10. Aviles A, Diaz NR, Neri N, et al: Angiocentric nasal T/natural killer cell lymphoma: A single centre study of prognostic factors in 108 patients. Clin Lab Haematol 22:215-220, 2000
11. Kim GE, Cho JH, Yang WI, et al: Angiocentric lymphoma of the head and neck: Patterns of systemic failure after radiation treatment. J Clin Oncol 18:54-63, 2000
12. Koom WS, Chung EJ, Yang WI, et al: Angiocentric T-cell and NK/T-cell lymphomas: Radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 59:1127-1137, 2004
13. Sakata K, Fuwa N, Kodaira T, et al: Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol 79:179-184, 2006
14. Chen JS, Lin KH, Lin DT, et al: Longitudinal observation and outcome of nonfamilial childhood haemophagocytic syndrome receiving etoposidecontaining regimens. Br J Haematol 103:756-762, 1998
15. Uno M, Tsuchiyama J, Moriwaki A, et al: In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A. Br J Haematol 113:1009-1014, 2001
16. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
17. Kim GE, Lee SW, Chang SK, et al: Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 61:261-269, 2001
18. You JY, Chi KH, Yang MH, et al: Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: A single institute survey in Taiwan. Ann Oncol 15:618-625, 2004
19. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
20. Lee J, Suh C, Park YH, et al: Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006
21. Yamaguchi M, Suzuki R, Kwong YL, et al: Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99:1016-1020, 2008
22. Lee SH, Ahn YC, Kim WS, et al: The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma. Haematologica 91:427-428, 2006
23. Kim HS, Kim KH, Kim KH, et al: Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: Extranodal natural killer/T-cell lymphoma. Leuk Lymphoma 50:757-763, 2009
24. Wang B, Lu JJ, Ma X, et al: Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity. Leuk Lymphoma 48:396-402, 2007
25. Au WY, Weisenburger DD, Intragumtornchai T, et al: Clinical differences between nasal and extranasal NK/T-cell lymphoma: A study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood 113:3931-3937, 2009